Results 1 to 10 of about 31,191 (142)

Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma

Computational and Structural Biotechnology Journal, 2023
As sorafenib is a first-line drug for treating advanced hepatocellular carcinoma, sorafenib resistance has historically attracted attention. However, most of this attention has been focused on a series of mechanisms related to drug resistance arising ...
Ruiqi Zheng, Shuang Weng, Jianping Xu, Zhuo Li, Yaru Wang, Zulihumaer Aizimuaji, Sheng Ma, Linlin Zheng, Haiyang Li, Wantao Ying, Weiqi Rong, Ting Xiao   +11 more
doaj   +3 more sources

Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis [PDF]

Journal of Experimental & Clinical Cancer Research, 2020
Background The identification of novel targets for recovering sorafenib resistance is pivotal for Hepatocellular carcinoma (HCC) patients. Mitophagy is the programmed degradation of mitochondria, and is likely involved in drug resistance of cancer cells.
Hong Wu, Tao Wang, Yiqiang Liu, Xin Li, Senlin Xu, Changtao Wu, Hongbo Zou, Mianfu Cao, Guoxiang Jin, Jinyi Lang, Bin Wang, Baohua Liu, Xiaolin Luo, Chuan Xu   +13 more
doaj   +3 more sources

Mechanism of sorafenib resistance associated with ferroptosis in HCC

Frontiers in Pharmacology, 2023
Hepatocellular carcinoma (HCC) is the most familiar primary hepatic malignancy with a poor prognosis. The incidence of HCC and the associated deaths have risen in recent decades.
Lingling Guo, Cuntao Hu, Mengwen Yao, Guang Han   +3 more
doaj   +3 more sources

Autophagy modulation attenuates sorafenib resistance in HCC induced in rats. [PDF]

Cell Death Dis, 2023
AbstractHepatocellular carcinoma (HCC) has risen as the villain of cancer-related death globally, with a usual cruel forecasting. For advanced HCC, sorafenib has been FDA approved as first line treatment. In spite of the bright potential that sorafenib demonstrated in studies, actual clinical results are limited owing to the massive occurrence of drug ...
Elleithi Y, El-Gayar A, Amin MN.
europepmc   +4 more sources

Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway [PDF]

Cell Death and Disease
Sorafenib is an antiangiogenic and antiproliferative chemotherapeutic drug that plays a crucial role in the treatment of patients with advanced hepatocellular carcinoma (HCC). However, resistance to sorafenib greatly limits its therapeutic efficacy. This
Ruimei Ren, Shan Zhang, Zhan Peng, Xiaomeng Ji, Hao Song, Qiuxiao Wang, Xiangyin Sun, Huiyu Wang, Yinying Dong   +8 more
doaj   +2 more sources

SMYD2 epigenetically activates BMP4/SMAD1/5/8/ID3 axis to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma [PDF]

Neoplasia: An International Journal for Oncology Research
Background: Drug resistance prominently hampers the effects of sorafenib in hepatocellular carcinoma (HCC). Epigenetics play important roles in drug resistance.
Shanshan Wang, Weicheng Wu, Zhen Shi, Mei Bin, Fengwei Zhang, Long Cai, Kaiqing Lin, Zhihui Li   +7 more
doaj   +2 more sources

Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation [PDF]

Frontiers in Pharmacology
BackgroundCurcumol, a bioactive sesquiterpenoid extracted from traditional Chinese medicine (TCM), has demonstrated potential in overcoming tumor drug resistance.
Ni Zhang, Xinchen Tian, Fen Liu, Xiaohan Jin, Xiaohan Jin, Jiaqi Zhang, Lingli Hao, Shulong Jiang, Shulong Jiang, Qingbin Liu, Qingbin Liu   +10 more
doaj   +2 more sources

Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC. [PDF]

Mol Cancer
Abstract Background and aims Sorafenib is a major nonsurgical option for patients with advanced hepatocellular carcinoma (HCC); however, its clinical efficacy is largely undermined by the acquisition of resistance. The aim of this study was to identify the key lncRNA involved in the regulation of the sorafenib response ...
Chan YT, Wu J, Lu Y, Li Q, Feng Z, Xu L, Yuan H, Xing T, Zhang C, Tan HY, Feng Y, Wang N.   +11 more
europepmc   +4 more sources

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma [PDF]

Journal of Biomedical Science, 2022
Abstract Background Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and has a high mortality rate worldwide. Sorafenib is the only systemic treatment demonstrating a statistically significant but modest overall survival benefit.
You-Liang Lai, Kai-Hung Wang, Hsing-Pang Hsieh, Wan-Ching Yen   +3 more
openaire   +3 more sources

Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance

Cells, 2022
Sorafenib is a small molecule that blocks tumor proliferation by targeting the activity of multi-kinases for the treatment of advanced hepatocellular carcinoma (HCC). Increasing sorafenib resistance following long-term treatment is frequently encountered.
Yung-Sheng Chang, Chien-Wei Su, San-Chi Chen, Yen-Ying Chen, Yuh-Jin Liang, Jaw-Ching Wu   +5 more
doaj   +1 more source